6.21亿！增长29.99%！英诺特最新年报

Financial Performance - The company achieved total operating revenue of 621.39 million, representing a year-on-year growth of 29.99% [2][5] - The net profit attributable to shareholders was 246.86 million, reflecting a year-on-year increase of 41.92% [2][5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 217.75 million, with a year-on-year growth of 48.08% [2][5] Cash Flow - The net cash flow from operating activities was 305.46 million, showing a year-on-year increase of 17.55% [5] - The net cash flow from investing activities was -63.07 million, an improvement from -429 million in the previous year [5] - The net cash flow from financing activities was -103 million, a decrease of 58.27 million year-on-year [5] Assets and Liabilities - The net assets attributable to shareholders at the end of 2024 were 1,993.39 million, an increase of 8.22% compared to the end of 2023 [1] - Total assets reached 2,212.46 million, reflecting a year-on-year growth of 7.11% [1] - Cash and cash equivalents increased by 84.86% compared to the previous year, with a rise in proportion to total assets by 5.85 percentage points [5] Company Overview - The company, Beijing Innotech Biotechnology Co., Ltd., focuses on the research, development, production, and sales of POCT rapid diagnostic products [6] - It specializes in the field of in vitro diagnostics, particularly in respiratory pathogen detection, and has developed multiple detection technologies [6] - The company has established a significant market position in respiratory pathogen detection, with products recognized by major children's hospitals [6] Research and Development - The company has built six major technology platforms, including immunochromatography and nucleic acid molecular detection [7] - R&D investment reached 97.17 million in 2024, a year-on-year increase of 82.95%, accounting for 15.64% of operating revenue [7]